S&P 500   5,253.30 (+0.09%)
DOW   39,787.51 (+0.07%)
QQQ   443.86 (-0.22%)
AAPL   171.65 (-0.96%)
MSFT   420.44 (-0.23%)
META   488.15 (-1.16%)
GOOGL   150.88 (+0.01%)
AMZN   180.38 (+0.31%)
TSLA   176.84 (-1.66%)
NVDA   904.39 (+0.21%)
NIO   4.54 (-2.78%)
AMD   180.60 (+0.56%)
BABA   72.46 (+1.22%)
T   17.66 (+0.63%)
F   13.24 (+1.38%)
MU   117.64 (-1.26%)
CGC   9.13 (-4.40%)
GE   175.14 (-2.76%)
DIS   122.56 (+1.31%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.24 (+1.01%)
XOM   116.14 (+1.02%)
S&P 500   5,253.30 (+0.09%)
DOW   39,787.51 (+0.07%)
QQQ   443.86 (-0.22%)
AAPL   171.65 (-0.96%)
MSFT   420.44 (-0.23%)
META   488.15 (-1.16%)
GOOGL   150.88 (+0.01%)
AMZN   180.38 (+0.31%)
TSLA   176.84 (-1.66%)
NVDA   904.39 (+0.21%)
NIO   4.54 (-2.78%)
AMD   180.60 (+0.56%)
BABA   72.46 (+1.22%)
T   17.66 (+0.63%)
F   13.24 (+1.38%)
MU   117.64 (-1.26%)
CGC   9.13 (-4.40%)
GE   175.14 (-2.76%)
DIS   122.56 (+1.31%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.24 (+1.01%)
XOM   116.14 (+1.02%)
S&P 500   5,253.30 (+0.09%)
DOW   39,787.51 (+0.07%)
QQQ   443.86 (-0.22%)
AAPL   171.65 (-0.96%)
MSFT   420.44 (-0.23%)
META   488.15 (-1.16%)
GOOGL   150.88 (+0.01%)
AMZN   180.38 (+0.31%)
TSLA   176.84 (-1.66%)
NVDA   904.39 (+0.21%)
NIO   4.54 (-2.78%)
AMD   180.60 (+0.56%)
BABA   72.46 (+1.22%)
T   17.66 (+0.63%)
F   13.24 (+1.38%)
MU   117.64 (-1.26%)
CGC   9.13 (-4.40%)
GE   175.14 (-2.76%)
DIS   122.56 (+1.31%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.24 (+1.01%)
XOM   116.14 (+1.02%)
S&P 500   5,253.30 (+0.09%)
DOW   39,787.51 (+0.07%)
QQQ   443.86 (-0.22%)
AAPL   171.65 (-0.96%)
MSFT   420.44 (-0.23%)
META   488.15 (-1.16%)
GOOGL   150.88 (+0.01%)
AMZN   180.38 (+0.31%)
TSLA   176.84 (-1.66%)
NVDA   904.39 (+0.21%)
NIO   4.54 (-2.78%)
AMD   180.60 (+0.56%)
BABA   72.46 (+1.22%)
T   17.66 (+0.63%)
F   13.24 (+1.38%)
MU   117.64 (-1.26%)
CGC   9.13 (-4.40%)
GE   175.14 (-2.76%)
DIS   122.56 (+1.31%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.24 (+1.01%)
XOM   116.14 (+1.02%)
NASDAQ:GLPG

Galapagos (GLPG) Stock Price, News & Analysis

$31.88
-1.07 (-3.25%)
(As of 02:09 PM ET)
Today's Range
$31.88
$32.18
50-Day Range
$32.68
$39.71
52-Week Range
$31.86
$45.21
Volume
194,593 shs
Average Volume
121,867 shs
Market Capitalization
$2.10 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.00

Galapagos MarketRank™ Stock Analysis

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
7.9% Upside
$34.50 Price Target
Short Interest
Bearish
2.24% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.85mentions of Galapagos in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.39) to ($0.14) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.20 out of 5 stars

Medical Sector

885th out of 939 stocks

Pharmaceutical Preparations Industry

405th out of 433 stocks

GLPG stock logo

About Galapagos Stock (NASDAQ:GLPG)

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of?various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG3667 that has completed Phase 1b trial; and GLPG5101 and GLPG5201, CD19 CAR-T product candidate manufactures at point-of-care, that is in Phase I/II in relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

GLPG Stock Price History

GLPG Stock News Headlines

AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Galapagos Enters Oversold Territory (GLPG)
Galapagos (NASDAQ:GLPG) Downgraded to "Hold" at StockNews.com
GLPG Oct 2024 45.000 put
GLPG Apr 2024 42.500 put
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Galapagos assumed with an Equal Weight at Morgan Stanley
GLPG Mar 2024 32.500 put
Galapagos price target lowered by EUR 4 at Barclays
Galapagos (GLPG) Gets a Hold from RBC Capital
GLPG Mar 2024 37.500 put
Galapagos FY 2023 Earnings Preview
GLPG Mar 2024 40.000 call
Galapagos presents at EBMT-EHA annual meeting 2024
Galapagos presents at EBMT-EHA annual meeting 2024
Best Times To Visit Galapagos Islands
Galapagos NV GLPG
Galapagos NV ADR (GLPG)
See More Headlines
Receive GLPG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galapagos and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GLPG
Employees
1,338
Year Founded
1999

Price Target and Rating

Average Stock Price Target
$41.00
High Stock Price Target
$44.00
Low Stock Price Target
$38.00
Potential Upside/Downside
+24.4%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Net Income
$229.10 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$259.40 million
Book Value
$40.42 per share

Miscellaneous

Free Float
63,979,000
Market Cap
$2.17 billion
Optionable
Optionable
Beta
0.26

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Paulus A. Stoffels M.D. (Age 62)
    Ph.D., CEO, Chairman, Interim Head of R&D
    Comp: $986.76k
  • Mr. Thad Huston (Age 54)
    CFO & COO
  • Ms. Sofie Van Gijsel
    Head of Investor Relations
  • Ms. Valeria Cnossen
    General Counsel
  • Marieke Vermeersch
    Head of Corporate Communication
  • Ms. Annelies Missotten
    Chief Human Resources Officer
  • Ms. Ellen Van Der Aar
    Head of Development
  • Mr. Philippe Alen
    Senior VP & Head of Business Development
  • Mr. Dirk De Naeyer
    Head of Development Operations
  • Ms. Alice Dietrich
    Head of Medical Affairs

GLPG Stock Analysis - Frequently Asked Questions

Should I buy or sell Galapagos stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galapagos in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GLPG shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLPG, but not buy additional shares or sell existing shares.
View GLPG analyst ratings
or view top-rated stocks.

What is Galapagos' stock price target for 2024?

5 analysts have issued 12 month price objectives for Galapagos' shares. Their GLPG share price targets range from $31.00 to $38.00. On average, they predict the company's stock price to reach $34.50 in the next year. This suggests a possible upside of 7.9% from the stock's current price.
View analysts price targets for GLPG
or view top-rated stocks among Wall Street analysts.

How have GLPG shares performed in 2024?

Galapagos' stock was trading at $40.65 on January 1st, 2024. Since then, GLPG shares have decreased by 21.4% and is now trading at $31.96.
View the best growth stocks for 2024 here
.

When is Galapagos' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our GLPG earnings forecast
.

What ETFs hold Galapagos' stock?

ETFs with the largest weight of Galapagos (NASDAQ:GLPG) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO) and ERShares NextGen Entrepreneurs ETF (ERSX).

What is Onno van de Stolpe's approval rating as Galapagos' CEO?

6 employees have rated Galapagos Chief Executive Officer Onno van de Stolpe on Glassdoor.com. Onno van de Stolpe has an approval rating of 100% among the company's employees. This puts Onno van de Stolpe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Galapagos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galapagos investors own include Gilead Sciences (GILD), Celyad Oncology (CYAD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), argenx (ARGX), AbbVie (ABBV), Biogen (BIIB), Pharming Group (PHGUF), Trade Desk (TTD) and Collegium Pharmaceutical (COLL).

When did Galapagos IPO?

Galapagos (GLPG) raised $161 million in an IPO on Thursday, May 14th 2015. The company issued 3,800,000 shares at a price of $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

Who are Galapagos' major shareholders?

Galapagos' stock is owned by a variety of institutional and retail investors. Top institutional investors include Primecap Management Co. CA (1.03%), Wellington Management Group LLP (0.75%), Stonepine Capital Management LLC (0.40%), Newtyn Management LLC (0.33%), Greenlight Capital Inc. (0.25%) and Point72 Asset Management L.P. (0.23%).

How do I buy shares of Galapagos?

Shares of GLPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GLPG) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners